MedTrace Logo

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

NCT06274268 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2024-07-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers.

The main question it aims to answer is :

Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment?

The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.

Conditions

Interventions

DIAGNOSTIC_TEST

Sarcopenia diagnostic test

the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.

Sponsors & Collaborators

  • Université Savoie Mont Blanc

    collaborator OTHER

  • Centre Hospitalier Metropole Savoie

    lead OTHER

Principal Investigators

  • Aurelie FILLON · Centre Hospitalier Metropole Savoie

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-24
Primary Completion
2027-05-01
Completion
2028-05-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06274268 on ClinicalTrials.gov